ERBB2 and breast carcinoma: To build an ERBB2 mRNA expression assay that tracks with clinical HER2 status, we combined the Short-HER HER2-positive cohort (n=434) with a HER2-negative cohort of patients newly diagnosed of early-stage breast cancer at Hospital Clinic (n=203) (Figure.